Natural Ozempic in the body? Science has found a way to produce GLP-1 inside the body for lasting weight loss

In a world that chases fitness and wellness amidst the hustle of daily lives, weight loss jabs have become the magic pills that keep the weight in check. As the consumption of ultra-processed foods (UPF) has grown, along with the sedentary lifestyle, obesity has emerged as the top malnutrition problem in the world’s young population, surpassing undernourishment. Hence, it’s imperative to pay attention to managing weight in order to lead a healthy life.

Enter Ozempic: the ‘magic pill’,’ is an injectable prescription medication used to manage type 2 diabetes and reduce cardiovascular risk in adults with the condition. It works by regulating insulin and suppressing appetite, and is often used as a weight-loss drug – although it is not approved by the Food and Drug Administration (FDA) for weight loss.

Although the semaglutide found in Ozempic is an effective ingredient when it comes to shedding pounds, these GLP-1 medications come with their fair share of side effects, too.

But what if the human body could produce its own Ozempic to manage the weight?

Turns out it actually can.

In a breakthrough that could soon revolutionize the treatment of diabetes and obesity, researchers say they’ve found a way to reprogram the pancreas so it produces the hormone GLP‑1 — the very one mimicked by drugs like Ozempic, Wegovy, and Mounjaro — without the need for ongoing injections. This approach could transform how we think about metabolic disease: instead of relying on weekly or daily medication, the body itself may eventually generate its own GLP-1. Although the research is still in early stages, the science is compelling and opens up exciting possibilities for the future of treatment.

A team at Duke University School of Medicine found that certain cells in the pancreas — specifically the so-called “alpha cells” — are more flexible than previously believed. Under the usual understanding, alpha cells produce the hormone glucagon, which raises blood sugar when needed. However, the new study shows they can shift gears and produce bioactive GLP-1, a hormone best known for enhancing insulin secretion and suppressing appetite.

​In detail, when the research team blocked the enzyme PC2 (which drives glucagon production) and thereby suppressed glucagon, the alpha cells increased production of PC1/3, which produces GLP-1. The result: more GLP-1, better insulin release from beta-cells, improved blood sugar control — at least in mice and pancreatic tissue studied.

GLP-1 is a key hormone in metabolic regulation: it signals insulin release in response to food, slows digestion, reduces appetite, and helps regulate blood sugar and body weight. Drugs like Ozempic and Mounjaro are synthetic GLP-1 receptor agonists — they mimic the hormone’s action. Millions now use them for type 2 diabetes and increasingly for weight loss. With the newly discovered mechanism, instead of injecting or taking a drug drawn from outside, the body itself could potentially become the factory for GLP-1.

That means:

Fewer (or even no) injections or pills needed.

Potentially more stable, physiological hormone production.

Possibly broader access and lower cost over time.

Researchers note the pancreas may have an in-built “backup plan” of sorts: when metabolic stress (such as a high-fat diet) occurs, alpha cells may shift towards GLP-1 production to support blood-sugar control.

To put it simply: the research is still at its very early stage. Most of the findings come from lab studies of human pancreatic tissue and mice models. For example, the Duke study found evidence of higher-than-expected GLP-1 production in alpha cells from human samples.

Apart from that, a biotech company, Fractyl Health, is developing a gene-therapy style approach (called “Rejuva”) that uses a viral vector to deliver DNA instructions to pancreatic cells so they produce GLP-1 themselves — and in mouse models, they reportedly achieved ~20% weight loss in three weeks. What’s more? Normal-weight mice also didn’t gain any weight and maintained healthy blood sugar levels after being treated and given a high-fat diet.

Fractyl Health cofounder and CEO Harith Rajagopalan told CNN, “It outperformed semaglutide.”

The approach works by using a small virus that can insert DNA instructions on how to produce GLP‑1 into cells.

Rajagopalan explained, “Because we are delivering it locally, we believe that we will need a very low dose of this virus, which helps gives us confidence in the potential safety in people.”

However, experts warn that such an approach in humans would likely be irreversible and could lead to long-term issues in the pancreas, which is responsible for blood sugar control.

On the other hand, Fractyl competitor RenBio used a different approach, by including the DNA instructions to make GLP-1 in a saline solution, which is then injected into muscle tissue. Short electrical pulses then allow the instructions to be delivered directly into cells, effectively “using the cell’s own machinery to turn it into a protein factory,” as per CNN.

Mice injected with the solution lost roughly 15% of their body weight, significantly more than mice in a placebo group, and kept the weight off for at least a year. Blood sugar level regulation improved as well.

If this line of research eventually succeeds, several outcomes are possible:

A one-time or infrequent treatment that reprograms pancreatic cells to produce GLP-1 might replace or greatly reduce the need for weekly GLP-1 injections.

Treatment of both type 2 diabetes and obesity could become more physiological — harnessing the body’s own cells rather than relying solely on drugs.

Access and cost might improve, especially in settings where injectable medications are expensive or logistically difficult.

However — and this is important — we are not “there” yet. For now, no human trials have published results for the pancreatic gene-therapy GLP-1 production approach. Safety, longevity of the effect, off-target consequences, and long-term hormone balance remain unknown. Therefore, patients should not abandon or change existing treatments based on this early research.